Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
Much of the therapeutic benefit of allogeneic transplant is by a graft versus tumor effect. Further data shows that transplant engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In the clinical setting, engraftment by competition...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/784213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172352054165504 |
|---|---|
| author | John L. Reagan Loren D. Fast Eric S. Winer Howard Safran James N. Butera Peter J. Quesenberry |
| author_facet | John L. Reagan Loren D. Fast Eric S. Winer Howard Safran James N. Butera Peter J. Quesenberry |
| author_sort | John L. Reagan |
| collection | DOAJ |
| description | Much of the therapeutic benefit of allogeneic transplant is by a graft versus tumor effect. Further data shows that transplant engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In the clinical setting, engraftment by competition alone is not feasible due to the need for large numbers of infused cells. Instead, low-level host irradiation has proven to be an effective engraftment strategy that is stem cell toxic but not myeloablative. The above observations served as the foundation for clinical trials utilizing allogeneic matched and haploidentical peripheral blood stem cell infusions with minimal conditioning in patients with refractory malignancies. Although engraftment was transient or not apparent, there were compelling responses in a heavily pretreated patient population that appear to result from the breaking of tumor immune tolerance by the host through the actions of IFNγ, invariant NK T cells, CD8 T cells, NK cells, or antigen presenting cells. |
| format | Article |
| id | doaj-art-cfe06c96b92e4cc9bec93380d40fc44c |
| institution | OA Journals |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-cfe06c96b92e4cc9bec93380d40fc44c2025-08-20T02:20:06ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/784213784213Nonengraftment Haploidentical Cellular Therapy for Hematologic MalignanciesJohn L. Reagan0Loren D. Fast1Eric S. Winer2Howard Safran3James N. Butera4Peter J. Quesenberry5Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USADivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USADivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USADivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USADivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USADivision of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School, Providence, RI 02903, USAMuch of the therapeutic benefit of allogeneic transplant is by a graft versus tumor effect. Further data shows that transplant engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In the clinical setting, engraftment by competition alone is not feasible due to the need for large numbers of infused cells. Instead, low-level host irradiation has proven to be an effective engraftment strategy that is stem cell toxic but not myeloablative. The above observations served as the foundation for clinical trials utilizing allogeneic matched and haploidentical peripheral blood stem cell infusions with minimal conditioning in patients with refractory malignancies. Although engraftment was transient or not apparent, there were compelling responses in a heavily pretreated patient population that appear to result from the breaking of tumor immune tolerance by the host through the actions of IFNγ, invariant NK T cells, CD8 T cells, NK cells, or antigen presenting cells.http://dx.doi.org/10.1155/2012/784213 |
| spellingShingle | John L. Reagan Loren D. Fast Eric S. Winer Howard Safran James N. Butera Peter J. Quesenberry Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies Advances in Hematology |
| title | Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies |
| title_full | Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies |
| title_fullStr | Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies |
| title_full_unstemmed | Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies |
| title_short | Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies |
| title_sort | nonengraftment haploidentical cellular therapy for hematologic malignancies |
| url | http://dx.doi.org/10.1155/2012/784213 |
| work_keys_str_mv | AT johnlreagan nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies AT lorendfast nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies AT ericswiner nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies AT howardsafran nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies AT jamesnbutera nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies AT peterjquesenberry nonengraftmenthaploidenticalcellulartherapyforhematologicmalignancies |